Specialty Chemicals company Balaji Amines announced Q3FY25 results Revenue from Operations for Q3FY25 stood at Rs 321 crore, as compared to Rs 356 crore in Q2FY25. Total volumes stood at 24,097 MT for Q3FY25 as against 26,348 MT in Q2FY25. For Q3FY25: Amines volumes stood at 7,515 MT. Amines Derivatives volumes stood at 8,809 MT. Specialty Chemicals volumes stood at 7,773 MT. EBITDA for Q3FY25 was Rs 54 crore, as compared to Rs 70 crore in Q2FY25 and Rs 83 crore in Q3FY24. EBITDA margin for Q3FY24 stood at 17% as against 20% in Q2FY25 and 21% in Q3FY24. PAT for Q3FY25 was Rs 31 crore as compared to Rs 41 crore in Q2FY25. Diluted EPS for Q3FY25 stood at Rs 10.24 per equity share as against Rs 12.65 in Q2FY25. D. Ram Reddy, Managing Director, said: “During Q3FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery. The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum. Additionally, the utilization of expanded capacities will contribute to margin enhancement, as some of our products progress through the final approval stages with end-user industries. This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers. Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the FY26. Our focus on inherent strengths and competencies positions us as a leading force in Amines and Specialty Chemicals, guiding us through market complexities towards greater excellence.” Result PDF
Specialty Chemicals company Balaji Amines announced Q2FY25 results Revenue from Operations for Q2FY25 stood at Rs 356 crore, as compared to Rs 393 crore in Q1FY25 Total volumes stood at 26,348 MT for Q2FY25 as against 28,071 MT in Q1FY25. For Q2FY25. Amines volumes stood at 7,616 MT. Amines Derivatives volumes stood at 8,685 MT. Specialty Chemicals volumes stood at 10,046 MT EBITDA for Q2FY25 was Rs 70 crore, as compared to Rs 74 crore in Q1FY25. EBITDA margin for Q2FY24 stood at 20% as against 19% in Q1FY25. PAT for Q2FY25 was Rs 41 crore as compared to Rs 46 crore in Q1FY25. Diluted EPS for Q2FY25 stood at Rs 12.65 per equity share as against Rs 13.36 in Q1FY25. On a standalone basis, we are a zero-debt company. D. Ram Reddy, Managing Director, said, “In the Q2 quarter, we reported a revenue of Rs 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment. While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters. Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units. Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India. Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence. As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities. With a clear focus on our strengths, we are set to advance as a leader in Amines and Specialty Chemicals." Result PDF